Cronos GroupSTU:7CI -0.99%84 PS Ratio is 6.75 as of Jul. 11, 2026, which is 84% below its 10-year median of 40.95. GuruFocus rates STU:7CI with a GF Score™ of 84/100 and a GF Value™ of €3.09 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 952 Drug Manufacturers companies, Cronos Group ranks worse than 79.73% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Cronos Group's share price is €2.404.
Cronos Group's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.36. Hence, Cronos Group's PS Ratio for today is 6.75.
The historical rank and industry rank for Cronos Group's PS Ratio or its related term are showing as below:
STU:7CI'
s PS Ratio Range Over the Past 10 Years
Min: 5.36 Med: 40.95 Max: 920
Current: 6.79
During the past 12 years, Cronos Group's highest PS Ratio was 920.00. The lowest was 5.36. And the median was 40.95.
STU:7CI's PS Ratio is ranked worse than 79.73% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.295
vs STU:7CI: 6.79
During the past 12 months, the average Revenue per Share Growth Rate of Cronos Group was 26.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 19.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 24.50% per year.
During the past 12 years, Cronos Group's highest 3-Year average Revenue per Share Growth Rate was 135.10% per year. The lowest was 19.00% per year. And the median was 32.90% per year.
Back to Basics: PS Ratio
Cronos Group (STU:7CI) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Cronos Group PS Ratio Related Terms
Cronos Group PS Ratio Historical Data
* Premium members only.
The historical data trend for Cronos Group's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cronos Group's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Cronos Group's PS Ratio for today is calculated as
Cronos Group's Share Price of today is €2.404. Cronos Group's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.36.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Cronos Group (STU:7CI) has a PS Ratio of 6.75 as of Jul. 11, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cronos Group and its competitors. This is 84% below median its historical median of 40.95. Over the past decade, Cronos Group's PS Ratio has ranged from 5.36 to 920.00. According to the industry distribution chart, Cronos Group ranks #759 out of 952 companies in the Drug Manufacturers industry, placing it in the top 79.7%.
Is Cronos Group's PS Ratio too high?
Cronos Group's current PS Ratio of 6.75 is 84% below median its 10-year median of 40.95. Over the past 10 years, this metric has ranged from a low of 5.36 to a high of 920.00. The Drug Manufacturers industry median PS Ratio is 2.30. Cronos Group's value of 6.75 is 194.1% above this industry median. Based on the distribution chart, Cronos Group ranks #759 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cronos Group has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #759 out of 952 companies for PS Ratio. This places Cronos Group in the lower half of its industry. The industry median PS Ratio is 2.30. Cronos Group's value of 6.75 is 194.1% above this benchmark. Historically, Cronos Group's own PS Ratio has ranged from 5.36 to 920.00 over the past decade. While the company's 10-year median is 40.95 vs. the industry median of 2.30, Cronos Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cronos Group's current PS Ratio of 6.75 is 194.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cronos Group and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current PS Ratio is 6.75, which is 84% below median its own 10-year median of 40.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (STU:7CI) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.09, compared to a current price of €2.40 — trading 22.2% below its estimated fair value. The current PS Ratio is 6.75, which is 84% below median its 10-year median of 40.95 and 194.1% above the Drug Manufacturers industry median of 2.30. Cronos Group's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Cronos Group (STU:7CI), the current PS Ratio is 6.75 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (STU:7CI) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of €2.40 is trading 22.2% below its estimated GF Value™ of €3.09.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for STU:7CI:
PS Ratio: 6.75 (84% below median its 10-year median of 40.95)
GF Value™: €3.09 vs. price of €2.40 (22.2% below fair value)
Industry Position: 194.1% above the Drug Manufacturers median (#759 of 952)
No single metric tells the full story. See the STU:7CI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
84GF Score
Get the complete analysis for STU:7CI
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7CI has been successfully added to your 
